Ook in 2026 kunt u een gift / donatie gebruiken als aftrekpost bij de inkomstenbelasting, omdat wij een ANBI status hebben. Mocht u onze website waarderen dan wilt u misschien een gift / donatie overmaken naar onderstaand rekeningnummer met vermelding gift 2026. 

NL79 RABO 0372931138 t.n.v. Stichting  Gezondheid Actueel in Terneuzen. BIC/SWIFTCODE RABONL2U. 


Zie ook in gerelateerde artikelen hiernaast of hieronder

21 november 2026:

Zie op onze website enkele andere artikelen met Helicobacter pylori in de titel: https://kanker-actueel.nl/NL/search.html?search_text=Helicobacter+pylori&search_in=title

21 november 2026: Bron: N Engl J Med 2026, d.d. 21 oktober 2026

In een recent studieverslag gepubliceerd d.d. 21 oktober 2026 in de NEJM met als titel: Helicobacter pylori-infectie — Vooruitgang, uitdagingen en de weg vooruit wordt een overzicht gegeven van de huidige behandelingen om een Helicobacter pylori infectie te voorkomen of patiënten met maagkanker die reeds geïnfecteerd zijn met de Helicobacter pylori bacterie te behandelen.

In het studieverslag Helicobacter pylori Infection — Advances, Challenges, and the Road Ahead dat slechts als abstract is in te zien, maar op bepaalde voorwaarden gratis in te zien of te downloaden worden deze punten besproken en heb ik vertaald met hulp van google translate:

  • Helicobacter pylori infectie is een overdraagbare infectieziekte en de belangrijkste risicofactor voor maagkanker; daarom moet eradicatietherapie = volledig vernietigen / uitroeien worden toegediend aan geïnfecteerde personen, tenzij dit  bij de patiënten door andere redenen niet wenselijk is.
  • • Screening en behandeling van de Helicobacter pylori bacterie op bevolkingsniveau is geschikt in regio's met een veel voorkomende Helicobacter pylori infectie en een hoge incidentie van maagkanker, maar is mogelijk niet praktisch. Een gezinsgerichte strategie, gericht op huisgenoten van geïnfecteerde personen, biedt een haalbaarder alternatief.
  • •De behandeling van een Helicobacter pylori infectie moet voldoen aan de principes van antimicrobiële bewaking en worden geleid door antimicrobiële gevoeligheidstesten. Verbetering en standaardisatie van veelgebruikte methoden zijn nodig om antimicrobiële gevoeligheidstesten als routine in de klinische praktijk te vestigen.
  • Viervoudige therapie op basis van het medicijn bismut en dubbele therapie met hoge dosis zijn geschikt als proefondervindelijke kuren voor zowel een eerstelijns behandeling als palliatieve behandeling;
  • Een op het lichaamsgewicht gebaseerde dosis amoxicilline wordt aanbevolen voor een combinatietherapie met hoge doses.
  • Nieuwe therapieën voor een Helicobacter pylori infectie zijn nodig, waaronder de ontwikkeling van nieuwe antimicrobiële middelen en effectieve vaccins.
Ik heb zelf het volledige studieverslag kunnen downloaden. Klik op de titel van het abstract. Als daar alleen het abstract verschijnt en u wilt het artikel in PDF formaat dan kan ik u dat wel toesturen.

Review
. 2026 Oct 22;395(16):1621-1633.
doi: 10.1056/NEJMra2414530.

Helicobacter pylori Infection - Advances, Challenges, and the Road Ahead

Affiliations

Abstract

The discovery of Helicobacter pylori has revolutionized the prevention and treatment of gastritis, peptic ulcers, and, most important, gastric cancer. In the past 40 years, enormous progress has been achieved in the clinical and basic research on H. pylori infection. However, challenges in preventing and treating H. pylori infection exist owing to the lack of an H. pylori vaccine and the ever-increasing resistance to antibiotics worldwide. This review summarizes the history of and key milestones in H. pylori research, provides an update on the understanding of the pathogenesis and global burden of H. pylori infection and the screening strategy for the primary prevention of gastric cancer, and focuses on the emerging trends in the management of H. pylori infection.

PubMed Disclaimer

Similar articles


Notes

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
The timeline in Figure 1 is dedicated to the memory of the late Nobel laureate Dr. J. Robin Warren (1937 to 2024).

Supplementary Material

Disclosure Forms (nejmra2414530_disclosures.pdf)

References

1.
Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-1315.
2.
Goodwin CS, Armstrong JA, Chilvers T, et al. Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb, nov., respectively. Int J Syst Bacteriol 1989;39:397-405 (https://www.microbiologyresearch.org/content/journal/ijsem/10.1099/00207713-39-4-397).
3.
Campylobacter pylori in gastroduodenal diseases: current views — future directions: proceedings of an international workshop: Copenhagen, 15 and 16 October 1987. Scand J Gastroenterol Suppl 1988;142:1-116.
4.
Olmedo L, Calvet X, Gené E, et al. Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg). Gut 2024;74:15-25.
5.
Correa P. Human gastric carcinogenesis: a multistep and multifactorial process — first American Cancer Society Award Lecture on cancer epidemiology and prevention. Cancer Res 1992;52:6735-6740.
6.
Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789.
7.
Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994;330:1267-1271.
8.
Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
9.
European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. Gut 1997;41:8-13.
10.
Malfertheiner P, Mégraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection — the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-180.
11.
Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353-1367.
12.
Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut 2022;71:1724-1762.
13.
Chey WD, Howden CW, Moss SF, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2024;119:1730-1753.
14.
Liou J-M, Malfertheiner P, Lee Y-C, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut 2020;69:2093-2112.
15.
Fock KM, Talley N, Moayyedi P, et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008;23:351-365.
16.
Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781.
17.
Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection — the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-664.
18.
Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6-30.
19.
Marshall B. Helicobacter connections. ChemMedChem 2006;1:783-802.
20.
Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch’s postulates for pyloric Campylobacter. Med J Aust 1985;142:436-439.
21.
Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis: the updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-1181.
22.
Price AB. The Sydney System: histological division. J Gastroenterol Hepatol 1991;6:209-222.
23.
Tomb JF, White O, Kerlavage AR, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997;388:539-547.
24.
Graham DY. The only good Helicobacter pylori is a dead Helicobacter pylori. Lancet 1997;350:70-72.
25.
Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016;62(10):e51-77.
26.
Moodley Y, Linz B, Bond RP, et al. Age of the association between Helicobacter pylori and man. PLoS Pathog 2012;8(5):e1002693-e1002693.
27.
Eaton KA, Brooks CL, Morgan DR, Krakowka S. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infect Immun 1991;59:2470-2475.
28.
Eaton KA, Morgan DR, Krakowka S. Motility as a factor in the colonisation of gnotobiotic piglets by Helicobacter pylori. J Med Microbiol 1992;37:123-127.
29.
Tang X, Tay A, Benghezal M, Marshall BJ, Tang H, Li H. Advances in Helicobacter pylori lipopolysaccharide structure and function. FEMS Microbiol Rev 2025;49:fuaf034-fuaf034.
30.
Gewirtz AT, Yu Y, Krishna US, Israel DA, Lyons SL, Peek RM Jr. Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate immunity. J Infect Dis 2004;189:1914-1920.
31.
Wunder C, Churin Y, Winau F, et al. Cholesterol glucosylation promotes immune evasion by Helicobacter pylori. Nat Med 2006;12:1030-1038.
32.
Gebert B, Fischer W, Weiss E, Hoffmann R, Haas R. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science 2003;301:1099-1102.
33.
Schmees C, Prinz C, Treptau T, et al. Inhibition of T-cell proliferation by Helicobacter pylori gamma-glutamyl transpeptidase. Gastroenterology 2007;132:1820-1833.
34.
Cover TL, Blanke SR. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol 2005;3:320-332.
35.
Takahashi-Kanemitsu A, Knight CT, Hatakeyama M. Molecular anatomy and pathogenic actions of Helicobacter pylori CagA that underpin gastric carcinogenesis. Cell Mol Immunol 2020;17:50-63.
36.
Zhou P, She Y, Dong N, et al. Alpha-kinase 1 is a cytosolic innate immune receptor for bacterial ADP-heptose. Nature 2018;561:122-126.
37.
Bauer M, Nascakova Z, Mihai A-I, et al. The ALPK1/TIFA/NF-κB axis links a bacterial carcinogen to R-loop-induced replication stress. Nat Commun 2020;11:5117-5117.
38.
Sharafutdinov I, Tegtmeyer N, Linz B, et al. A single-nucleotide polymorphism in Helicobacter pylori promotes gastric cancer development. Cell Host Microbe 2023;31(8):1345-1358.e6.
39.
Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010;23:713-739.
40.
Malfertheiner P, Camargo MC, El-Omar E, et al. Helicobacter pylori infection. Nat Rev Dis Primers 2023;9:19-19.
41.
Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M. Helicobacter pylori and extragastric diseases: a review. World J Gastroenterol 2018;24:3204-3221.
42.
Li J, Liao T, Chua EG, et al. Helicobacter pylori outer membrane vesicles: biogenesis, composition, and biological functions. Int J Biol Sci 2024;20:4029-4043.
43.
Chmiela M, Walczak N, Rudnicka K. Helicobacter pylori outer membrane vesicles involvement in the infection development and Helicobacter pylori-related diseases. J Biomed Sci 2018;25:78-78.
44.
Chen Y-C, Malfertheiner P, Yu H-T, et al. Global Prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022. Gastroenterology 2024;166:605-619.
45.
Shah SC, Halvorson AE, Lee D, et al. Helicobacter pylori Burden in the United States according to individual demographics and geography: a nationwide analysis of the veterans healthcare system. Clin Gastroenterol Hepatol 2024;22(1):42-50.e26.
46.
Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 2015;136:487-490.
47.
Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol 2023;20:338-349.
48.
Usui Y, Taniyama Y, Endo M, et al. Helicobacter pylori, homologous-recombination genes, and gastric cancer. N Engl J Med 2023;388:1181-1190.
49.
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229-263.
50.
National Cancer Institute. Cancer stat facts: stomach cancer (https://seer.cancer.gov/statfacts/html/stomach.html).
51.
Plein K, Madisch A, Stolte M, Hotz J. Short-term changes in Helicobacter pylori gastritis and bulbitis during and after 2 weeks of treatment with omeprazole and amoxicillin in duodenal ulcer patients. Z Gastroenterol 2001;39:503-510.
52.
Weyermann M, Rothenbacher D, Brenner H. Acquisition of Helicobacter pylori infection in early childhood: independent contributions of infected mothers, fathers, and siblings. Am J Gastroenterol 2009;104:182-189.
53.
Chiang T-H, Chang W-J, Chen SL-S, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut 2021;70:243-250.
54.
Hwang Y-J, Kim N, Lee HS, et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication — a prospective study for up to 10 years. Aliment Pharmacol Ther 2018;47:380-390.
55.
Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-397.
56.
Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med 2018;378:1085-1095.
57.
Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut 2020;69:2113-2121.
58.
Moss SF, Shah SC, Tan MC, El-Serag HB. Evolving concepts in Helicobacter pylori management. Gastroenterology 2024;166:267-283.
59.
Ding S-Z, Du Y-Q, Lu H, et al. Chinese consensus report on family-based Helicobacter pylori infection control and management (2021 edition). Gut 2022;71:238-253.
60.
Deane C, Kelly O, O’Morain C. Disparities in gastric cancer screening worldwide. Cancer Screen Prev 2024;3:184-190 (https://www.xiahepublishing.com/2835-3315/CSP-2024-00008).
61.
Talley NJ, Fock KM, Moayyedi P. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol 2008;103:510-514.
62.
Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996;348:150-154.
63.
Shah SC, Wang AY, Wallace MB, Hwang JH. AGA clinical practice update on screening and surveillance in individuals at increased risk for gastric cancer in the United States: expert review. Gastroenterology 2025;168(2):405-416.e1.
64.
In H, Adams A, Ho S, et al. Pepsinogen and Helicobacter pylori: serum biomarkers for gastric cancer risk in a diverse United States population. Surg Oncol Insight 2024;1:100086-100086 (https://www.surgoncinsight.org/article/S2950-2470(24)00095-1/pdf).
65.
Rauws EA, Langenberg W, Houthoff HJ, Zanen HC, Tytgat GN. Campylobacter pyloridis-associated chronic active antral gastritis: a prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988;94:33-40.
66.
Thijs JC, van Zwet AA, Moolenaar W, Wolfhagen MJ, ten Bokkel Huinink J. Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects. Am J Gastroenterol 1996;91:93-97.
67.
Tefera S, Berstad A, Bang CJ, et al. Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain). Am J Gastroenterol 1996;91:935-941.
68.
Bazzoli F, Zagari RM, Fossi S, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994;6:773-778 (https://journals.lww.com/eurojgh/fulltext/1994/09000/short_term_low_dose_triple_therapy_for_the.4.aspx).
69.
Lamouliatte H. Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole in clinical studies. J Clin Gastroenterol 1995;20:Suppl 1:S28-S31.
70.
Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter 1996;1:138-144.
71.
Lind T, Mégraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116:248-253.
72.
Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology 2018;155(5):1372-1382.e17.
73.
Hong T-C, El-Omar EM, Kuo Y-T, et al. Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2024;9:56-67.
74.
Zhou L, Lu H, Song Z, et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J (Engl) 2022;135:2899-2910.
75.
Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology 2021;160:1831-1841.
76.
Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 2016;151(1):51-69.e14.
77.
Liu D-S, Wang Y-H, Zeng Z-R, et al. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. Clin Microbiol Infect 2018;24(7):780.e5-780.e8.
78.
Gisbert JP. Rifabutin for the treatment of Helicobacter pylori infection: a review. Pathogens 2020;10:15-15.
79.
Qian H-S, Li W-J, Dang Y-N, et al. Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy. Am J Gastroenterol 2023;118:627-634.
80.
Yang J, Zhang Y, Fan L, et al. Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori. Am J Gastroenterol 2019;114:437-445.
81.
Gao W, Liu J, Wang X, et al. Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy. Gut 2024;73:1414-1420.
82.
Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology 2019;157:44-53.
83.
Hulten KG, Genta RM, Kalfus IN, Zhou Y, Zhang H, Graham DY. Comparison of culture with antibiogram to next-generation sequencing using bacterial isolates and formalin-fixed, paraffin-embedded gastric biopsies. Gastroenterology 2021;161(5):1433-1442.e2.
84.
Wang L, Li Z, Tay CY, Marshall BJ, Gu B, Guangdong Center for Quality Control of Clinical Gene Testing and Study Group of Chinese Helicobacter pylori Infection and Antibiotic Resistance Rates Mapping Project (CHINAR-MAP). Multicentre, cross-sectional surveillance of Helicobacter pylori prevalence and antibiotic resistance to clarithromycin and levofloxacin in urban China using the string test coupled with quantitative PCR. Lancet Microbe 2024;5(6):e512-e513.
85.
Wang Y-H, Li Z, Wang L, et al. A systematic review and meta-analysis of genotypic methods for detecting antibiotic resistance in Helicobacter pylori. Helicobacter 2018;23(2):e12467-e12467.
86.
Song Z, Zhou L, Wang W, et al. Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial. Lancet Infect Dis 2026;26:101-110.
87.
Angsantikul P, Thamphiwatana S, Zhang Q, et al. Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery against Helicobacter pylori infection. Adv Ther (Weinh) 2018;1:1800016-1800016.

Plaats een reactie ...

Reageer op "Helicobacter pylori heeft nieuwe behandelingen nodig om een Helicobacter pylori infectie te voorkomen en zo maagkanker te voorkomen of behandelen. Zie overzichtstudie waaronder de ontwikkeling van nieuwe antimicrobiële middelen en effectieve vaccins."


Gerelateerde artikelen
 

Gerelateerde artikelen

Preventie: Helicobacter pylori >> ATRA - all-trans-retinoic-acid >> Cranberrysap remt groei en >> Vitamine C vermindert kans >>